Late adriamycin-related cardiotoxicity of dose-dense and intense sequential doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer.

被引：0

作者：

Abu-Khalaf, M ^{[1
]}

Juneja, V ^{[1
]}

Chung, G ^{[1
]}

DiGiovanna, M ^{[1
]}

Wackers, F ^{[1
]}

Lee, F ^{[1
]}

Burtness, B ^{[1
]}

机构：

[1] Yale Univ, Sch Med, New Haven, CT USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S109 / S110

页数：2

共 50 条

[1] Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Maysa M. Abu-Khalaf
Vinni Juneja
Gina G. Chung
Michael P. DiGiovanna
Rebecca Sipples
Meghan McGurk
Daniel Zelterman
Bruce Haffty
Michael Reiss
Frans J. Wackers
Forrester A. Lee
Barbara A. Burtness
[J]. Breast Cancer Research and Treatment, 2007, 104 : 341 - 349
[2] Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
Abu-Khalaf, Maysa M.
Juneja, Vinni
Chung, Gina G.
DiGiovanna, Michael P.
Sipples, Rebecca
McGurk, Meghan
Zelterman, Daniel
Haffty, Bruce
Reiss, Michael
Wackers, Frans J.
Lee, Forrester A.
Burtness, Barbara A.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 104 (03) : 341 - 349
[3] Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting
Burtness, B
Windsor, S
Holston, B
DiStasio, S
Staugaard-Hahn, C
Abrantes, J
Kneuper-Hall, R
Farber, L
Orell, J
Bober-Sorcinelli, K
Haffty, BG
Reiss, M
[J]. CANCER JOURNAL, 1999, 5 (04): : 224 - 229
[4] Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
Hudis, C
Seidman, A
Baselga, J
Raptis, G
Lebwohl, D
Gilewski, T
Moynahan, M
Sklarin, N
Fennelly, D
Crown, JPA
Surbone, A
Uhlenhopp, M
Riedel, E
Yao, TJ
Norton, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) : 93 - 100
[5] Long-Term Efficiency and Toxicity of Adjuvant Dose-Dense Sequential Adriamycin-Paclitaxel-Cyclophosphamide Chemotherapy in High-Risk Breast Cancer
Kelemen, Gyoengyi
Uhercsak, Gabriella
Ormandi, Katalin
Eller, Jozsef
Thurzo, Laszlo
Kahan, Zsuzsanna
[J]. ONCOLOGY, 2010, 78 (3-4) : 271 - 273
[6] Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient
Hikino H.
Kawashima M.
Yamada T.
Ozaki N.
[J]. International Journal of Clinical Oncology, 2006, 11 (4) : 332 - 335
[7] Dose-dense sequential Adriamycin-paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer
Kahan, Z
Uhercsak, G
Hajnal-Papp, R
Boda, K
Thurzo, L
[J]. ONCOLOGY, 2005, 68 (4-6) : 446 - 453
[8] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
Fountzilas, G
Papadimitriou, C
Aravantinos, G
Nicolaides, C
Stathopoulos, G
Bafaloukos, D
Kalofonos, H
Ekonomopoulos, T
Skarlos, D
Pavlidis, N
Dimopoulos, AM
[J]. ONCOLOGY, 2001, 60 (03) : 214 - 220
[9] Dose-dense doxorubicin, docetaxel and cyclophosphamide as sequential neoadjuvant therapy for high-risk breast cancer: a pilot study.
Link, JS
Forsthoff, CA
Ibarra, J
Rogers, LW
Magy, F
Maya, KA
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S59 - S60
[10] Dose-dense and sequential strategies in adjuvant breast cancer therapy
Untch, M
Von Koch, F
Crohns, C
Sobotta, K
Kahlert, S
Konecny, G
Hepp, H
[J]. ONCOLOGY-NEW YORK, 2001, 15 (05): : 14 - 20

← 1 2 3 4 5 →